AlphAIAlphAI — Financial news for AI agents
MSNMAY 213 min read$BOLT

Bolt Biotherapeutics, Inc. (BOLT) reports Q1 loss, lags revenue estimates

Bolt Biotherapeutics, Inc. (BOLT) reported a wider-than-anticipated loss and revenue that fell short of analyst estimates for the first quarter. The company announced a loss of $0.62 per share, exceeding the average analyst estimate of a $0.57 loss, and posted revenues of $2.20 million, significantly lower than the $5.53 million expected.

Original reporting
MSN
Published May 21, 2026, 3:40 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 21, 2026, 4:00 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$BOLT
Bearish
medium confidence
Mentioned
$BOLT
Relevance
6/10
AlphAI data visualization · based on MSN
Decision brief

The 30-second read

$BOLTBearishMed
01

Why it matters

The earnings miss has led to increased bearish sentiment, likely causing a decline in stock price. Sector-wide effects may include increased volatility in biotech indices.

02

Market read

High relevance for biotech investors and traders focusing on sector momentum and earnings reports.

03

What to watch

Potential positive catalysts such as pipeline advancements or strategic collaborations not reflected in current earnings

Relevance 6/10Timing: Immediate to short-term trading window

Background

Bolt Biotherapeutics operates in the biotech sector, focusing on immuno-oncology therapies. Recent earnings report showed wider losses and revenue shortfalls, raising concerns about short-term performance.

Company-level read

Ticker impact

$BOLTBearishMedium confidence
Context

Primary focus due to recent earnings report

Expected impact

Short-term decline expected; potential rebound if fundamentals improve

Evidence & confidence

Earnings miss and negative sentiment suggest downward pressure, but biotech stocks can be volatile with potential for recovery based on future developments.

Market effects

Sector

Negative impact on biotech sector indices; potential spillover to life sciences stocks

Regional

Limited regional impact; company primarily US-focused

Global

Moderate; biotech sector is globally interconnected but specific to US market

Counterpoint

What could challenge this read

The earnings miss may be a temporary setback; company could rebound with upcoming clinical trial results or partnerships

Key entities

  • Company
    Bolt Biotherapeutics

    A biotech firm specializing in immuno-oncology therapies.

Read at source← All news

Related articles

OCT 23
$BOLTHigh

Bolt Biotherapeutics, Inc. (BOLT): Completion of Acquisition or Disposition of Assets

Bolt Biotherapeutics, Inc. (BOLT) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Bolt Biotherapeutics Announces Acquisition of Prana Therapies and $120 Million Concurrent Private Placement to Advance PRA-216 in Multiple High-Value Inflammatory Indications • Transactions position the company to advance Prana’s pipeline of next-generation, half-lif

SEC EDGAR 8-K2 min
OCT 23
$BOLTMed

Bolt Biotherapeutics Announces Acquisition Of Prana Therapies, $120 Mln Concurrent Private Placement

Bolt Biotherapeutics (BOLT) acquired Prana Therapies via a stock-for-stock deal, exchanging shares for Prana's equity. Bolt also secured $120 million in a private placement, issuing Series D preferred stock and warrants. The funds will support operations into 2028. Prana's co-founder, Sheila Gujrathi, joined Bolt's board as chief strategy officer. BOLT shares closed at $4.19 on Nasdaq.

rttnews.com1 min
OCT 23
$BOLTHighAI 8/10

Bolt Biotherapeutics acquires Prana in reverse merger deal

Bolt Biotherapeutics (BOLT) acquired Prana Therapies in a reverse merger, raising $120M with potential for $60M more. Post-merger, Prana shareholders own 51.7% of Bolt. The combined company will advance Prana's INSPIRE platform, with Phase 2 data expected in Q2 2027. Sheila Gujrathi, Prana's co-founder, joins Bolt's board.

investing.com2 min
OCT 23
$BOLTMedAI 8/10

A $120 million financing is expected to fund Bolt's operations into 2028

Bolt Biotherapeutics (BOLT) acquired Prana Therapies, securing $120M in financing, with up to $60M more possible. The deal advances Prana's pipeline, including PRA-216, a bispecific antibody in Phase 2 trials for asthma, COPD, and atopic dermatitis. Data from all trials is expected in Q2 2027. Dr. Sheila Gujrathi, Prana's co-founder, joins Bolt's executive team. The financing is expected to fund operations into 2028.

stocktitan.net2 min